Asia Pacific's Leading MedTech Conference

John Collings is a senior-level leader with more than 20 years of experience in the medical technology and pharmaceutical industry. He started his career with Stryker in 2016, and he was appointed to President of Stryker Asia Pacific in 2020 after assuming leadership roles with increasingly expanded responsibilities.

John is focused on driving and developing high-performing teams across the region. Having lived and worked in seven different countries, John embraces diversity and inclusion. This lays the foundation in developing mission-driven, diverse and inclusive teams that has been key to Stryker’s success. Together with Stryker’s customers, the dynamic team delivers customer-centric and differentiated innovation that drives optimal patient outcomes.

Dr. Thomas Schinecker has been Chief Executive Officer of the Roche Group since 2023. He began his career at Roche in 2003 as part of a management development program. This was followed by various roles across six countries and three continents. Throughout his time at Roche, he served as Head of Marketing and Sales in Austria, Lifecycle Leader for Diagnostics’ Sequencing Solutions and General Manager of Roche Diagnostics in Sweden as well as in Germany. For two years, he led Roche Diagnostics’ largest business unit including Research and Development, before taking over the Diagnostics Division, which he led from October 2019 to December 2022. Dr Thomas Schinecker was born in Germany with German and Austrian citizenship and grew up in Singapore. He studied genetics in Salzburg, Austria, and received his PhD in molecular biology from New York University in 2003.

Dr Jordan Nguyen is a leading Australian engineer, inventor and innovator, who is committed to improving as many lives as possible, as well as becoming a driving force behind both human and technological evolution as we move into the future.

An internationally renowned engineer for humanity, Jordan designs life-changing technologies to transform the lives of people with disabilities and the elderly through his role as founder of Psykinetic, a social business committed to bringing positive, sustainable and life-altering change. He also shares his adventures through documentaries across the world. Inspired by human endeavour, Jordan has big ambitions to see our world step consciously and creatively into a better future.

Mr. Shinjiro Sato has been the President and CEO of the company since 2017. Previously, he served as the Director and Managing Executive Officer from 2015 to 2017; Director and Senior Executive Officer from 2012 to 2015; Senior Executive Officer from 2012 to 2014; Group President of Cardiac and Vascular Business Group from 2011 to 2012; and Executive Officer, General Manager of Strategic Planning Dept. from 2010 to 2011. Mr. Sato served at Arthur Andersen Business Consulting (currently PwC Japan Group) from 1999 to 2004. He started his career at Joined Toa Nenryo Kogyo KK (currently JXTG Nippon Oil & Energy Corporation) in 1984.

Farhana Nakhooda, GM & SVP Health Catalyst, Asia Pacific, leads the overall vision and growth strategy of the Health Catalyst business across Asia Pacific. She is passionate about improving healthcare outcomes, access to care as well as decreasing healthcare costs across the APAC region. She has extensive experience with engagement at the intersection of medicine, technology, AI and analytics. Prior to joining Health Catalyst, Farhana was the IBM Healthcare & Life Sciences solutions leader for Asia Pacific for 18 years where she played a key role in digitally enabling healthcare transformation projects across Asia Pacific, Eastern Europe and Middle East/Africa. She has more than 25 years of international experience in the healthcare and life sciences industry as a medical researcher and as a subject matter expert. Farhana has a Bachelor of Science degree (with Honors), in which she majored in Biology and Biochemistry, at the University of British Columbia. She completed her MBA at Monash Mt Eliza Business School in Melbourne, Australia.

Feng Dong is the Vice President of Asia Region-Led Markets for the Global Regions. He has been in the medical and healthcare industry for more than 30 years, and since joining Medtronic in 2004, has held several strategic positions, most recently serving as the Vice President and Managing Director of Medtronic Korea and Vice President for the Peripheral Vascular Operating Unit (OU) in Japan.

He is strongly committed to the principles of diversity, equity, and inclusion and is a firm believer that fostering a culture of inclusivity and respect can create innovative teams and make a positive impact on the lives of our patients.

Born in China, Feng Dong holds a Bachelor of Medicine from the University of Chinese Medicine School and spent five years in orthopedics treating patients in China. In his free time, Feng Dong enjoying spending time with his family and staying active through badminton, running, hiking, mountaineering, and skiing.

Joanna is a passionate business leader with over two decades’ international experience in healthcare. She was appointed VP for Asia in April 2023, and is responsible for overseeing the business across China, Hong Kong/Taiwan, Korea, Malaysia, India, Singapore, Thailand, Vietnam, Indonesia & the Philippines.

Joanna first joined Baxter in 2006, in an Asia Pacific Business Development role, before being promoted to a number of leadership roles across the region. She was appointed as Business Unit Director for BioScience in China in 2008, and moved to Hong Kong in 2010, having been appointed as General Manager. In 2015, she further expanded her role as General Manager of Hong Kong and Taiwan. In 2019, she was appointed VP for South East Asia, covering 6 markets – the region grew to include India in 2021.

Joanna’s passion for healthcare was sparked during her early experiences at Novartis Consumer Health and McKinsey & Co where she primarily focused on healthcare clients.

Joanna holds a Bachelor’s Degree in Management Information Systems from Fudan University, China and Master of Business Administration from Columbia Business School, New York.

Biten Kathrani is currently the Head of R&D for APJ region and Global Special Contact Lens Research (Drug Eluting lenses, Myopia, Beauty Lenses) at Johnson & Johnson Vision Care. Based in Singapore, he is a part of the global Vision R&D Leadership team. He is responsible for leading J&J Vision’s largest strategic Public Private Partnership (PPP) program on childhood Myopia Singapore Eye Research Institute co-sponsored by Singapore EDB and A*STAR.

In his medtech career spanning 28+ years, Biten has setup and led 6 Global R&D centers for MNC’s and new venture start-ups. He has held organizational leadership roles in R&D, Innovation, and new ventures in APAC (China, Singapore & India) and USA. He also spent 3 years leading External innovation programs at J&J’s Corporate Office of Science & Technology in New Brunswick, NJ, USA developing new technology partnerships at universities, seed stage start-ups and venture funded companies for J&J across medtech, consumer and pharma.

Biten is well networked in the healthcare innovation ecosystem in Singapore and APAC and is a sought-after mentor, coach and evaluation panel member at healthcare incubator and accelerator programs. He is engaged in diverse capacities with innovation programs like Enterprise Singapore’s Startup Sg Tech, Nanyang Technology University – JumpStart (Joint University Medtech Program), NUHS – GRIP program, Stanford Biodesign program – USA, Singapore and India chapters, Medtech Innovator Program, Medtech Actuator and Founders Forum, India, a volunteer organization to support medtech startups through their innovation commercialization and scale up journey.

He has lead R&D programs and talented teams to deliver 20+ diverse medical devices and 50+ patents covering single use disposable devices, capital equipment & instruments and software & connected health platforms for Class III implantables. Biten has managed large R&D organization footprint of 200+ employees and brings general management & organizational leadership skills. He considers future R&D leadership talent development (10+ Directors and Sr. Managers) amongst his most satisfying achievements.

Under his leadership, Boston Scientific’s Global India R&D center won the NASSCOM Innovation Excellence Award for GIC’s (Global Inhouse Capability Centers) in 2018.

Biten holds an MBA from the ivy league Wharton Business School, Univ. of Pennsylvania, an M. Tech in Biomedical Engineering from Indian Institute of Technology, Mumbai, a Post Diploma in Intellectual Property Management, and is a certified Patent Agent.

He is very passionate about community giving and currently leads cross sector Singapore Community Impact at Johnson & Johnson, focused on mental wellness, eye health, STEM for youth and disaster management.

Praneet brings with him nearly 30 years of experience altogether in working with and leading multi-cultural teams in both medical devices and management consulting. Presently, Praneet serves with Teleflex, a global provider of medical technologies and leads their businesses across all of Asia Pacific, responsible for over 700 colleagues.

Praneet has previously served at Fresenius Medical Care and Baxter across multiple roles in sales & marketing and financial planning & analysis.

Praneet in a Management Graduate from the University of Delhi and has stayed and worked in Hong Kong and India, other than in Singapore where he now resides.

Christian joins B. Braun Medical Industries in Malaysia with 20 years of experience serving the Group in Germany. Starting at Avitum as a trainee, he was also identified early in his career to train in the United States of America under the Marketing specialization. He then moved up the ranks through various local and global functions, which included strategic Portfolio Management, 0PEX, Production Management, Plant Controller, Investment and Projects.

Prior to this role, he was leading a subsidiary of B. Braun as Managing Director, where he was responsible for the overall management of the site. There, he developed a production and plant strategy through 2030. His current position is Christian’s first posting abroad since he joined B. Braun Melsungen AG in 2003.

Christian graduated from the University of Applied Sciences,A nsbach,G ermanyi n Industrial Engineering with focus on Medical Technologies. In his free time, he enjoys exploring the world with his family, which includes his three children, or sweating it out in the intense game of
handball or the relaxing pace of tennis.

Cecelia is the Vice President of Stryker in Asia Pacific, where she oversees strategy, business development, and R&D across the region. 

Cecelia joined Stryker in 2014 as Senior Director, Head of Business Development for International Markets and led mergers and acquisitions (M&A) and strategic partnerships for APAC, LatAM, the Middle East, and Africa regions. In 2017, Cecelia was appointed General Manager of Trauson, a local orthopedics company acquired by Stryker. 

Before joining Stryker, Cecelia held leadership roles across finance and management in Coca-Cola Company and Life Technologies Corporation (now Thermo Fisher). Cecelia started her career in investment banking with Lehman Brothers in capital markets and equity research in Hong Kong, New York, and Los Angeles.

Cecelia holds a Bachelor of Arts in Economics and East Asian Studies from Wesleyan University and a Master of Business Administration from UCLA. She is also a Chartered Financial Analyst (CFA).

Ajay has over two decades of deep industry expertise in MedTech and a proven track record of building high-performing teams across the U.S., Middle East, and Asia Pacific. Using his experience from roles across APAC, including key markets like China, Japan, Korea, India, and SEA, Ajay has successfully built his sales, marketing, and commercial leadership career with some of the top med device companies in the world. After spending the last three years working in V.C., startups, and consulting, Ajay continues to expand his extensive people-oriented network that covers the U.S., the Middle East, and APAC.

Ren Jun Lim is a Principal of the Intellectual Property and Technology (IPTech) Practice Group at Baker & McKenzie Wong & Leow. He represents local and international clients in both contentious and non-contentious intellectual property matters. He also advises on a full range of healthcare, as well as consumer goods-related legal and regulatory issues. Ren Jun co-leads Baker McKenzie Wong & Leow’s Healthcare as well as Consumer Goods & Retail industry groups. He keenly advises on a full range of issues relating to the healthcare industry. These include regulatory compliance in respect of digital healthcare, telemedicine, drugs, medical devices, health supplements, food products and cosmetics; clinical trials; product liability/recall issues; data exclusivity; patent linkage; competition; and anti-corruption issues.

Astra is responsible for leading external partnership and M&A initiatives for Johnson & Johnson MedTech in China, supporting the company’s innovation and growth agenda. She is also a member of the JJMT China Management Board and will assume responsibility for the Business Development function in China.

Astra joins us with extensive leadership and transaction experience from GE, where she led business development and marketing activities in greater China in support of GE businesses’ strategic marketing and inorganic growth initiatives.

Prior to this Growth Leader role, she served as GE China’s Managing Director for Corporate Business Development beginning in 2007. In this role, she led M&A activities in various industries, such as energy, mining, aviation, security and industrial intelligent platforms.

In addition to her experience in GE, Astra served as Corporate Development Director for Cargill in Asia, a leading global agricultural company.

Prior to that, Astra spent over 17 years in Motorola in market research, M&A and Venture Capital in Asia, where she was the founding member of Motorola Venture in China in 2004.

Astra received her MBA from J.L. Kellogg Graduate School of Management/University of Science and Technology in Hong Kong and a Bachelor of Economics from Macquarie University in Sydney, Australia.

Jessie Qiu is a global C-level finance leader with 20 years of experience. Currently leading a large portfolio of over 300 finance professionals in Grab, she spearheads Finance to support the business expansion at the rate of 2X-3X per annum.

A result and data-driven finance leader, she builds her experience across a wide range of industries such as fin-tech, digital payment, lending, healthcare, manufacturing, technology and services. Prior to Grab, she worked for various fortune 500 companies such as Oracle, Teradata and Reckitt Benckiser.
She is proven to be strategic-minded, forward-thinking, and a trusted business partner. Her vision is to unlock business growth with data analytics, promote finance efficiency with automation and drive company-wide cost-efficiency transformation. She has lead finance transformation projects like building Financial data warehouse, SSC set up, ERP implementation, procurement transformation etc. She is also specialized in hand-picking high-performance finance leaders, onboarding, nurturing and motivating them to grow in her finance organization.

She holds a master’s degree from Sydney University and an Australian CPA membership since 2001. Most recently, she completed her Harvard Business School Executive Program. She has also shared her transformation leadership experience as a penal speaker in a recently held Softbank CFO conference in California.

Glenda is Director of Government Affairs and Market Access, APACMed secretariat. Glenda brings over a decade of policy experience working at the nexus of government, business and civil society – to accelerate partnerships and policies improving patient access to care. Glenda holds a masters’ degree in social sciences from University of Chicago and bachelors of science in government and economics from LSE.

Benish joined APACMed in 2021 to support the Digital Health committee. Since October 2021, she has been working in the Government Affairs & Market Access committee to help build long term relationships with government stakeholders and promote smoother, more well-defined market access pathways.  

Benish has close to a decade of prior experience in developing evidence based tailored therapeutic protocols for patient centric care in a multidisciplinary team at a tertiary hospital in India. Apart from that, while teaching as an Assistant Professor at a university, she also explored various innovative research projects which led her to pursue a Doctor of Philosophy. In Singapore, Benish completed an MBA in strategy & digital leadership from ESSEC Business School. 

Benish is involved in various volunteering activities in Singapore and enjoys exploring new places and spending time with her family and friends.

Pravin is MTAA’s Policy Manager with a strong focus on developing and advocating on industry policy positions across the MTAA membership.  Pravin joined MTAA in January 2022 and oversees numerous committees and working groups that focus on local industry development, procurement and supply chain matters for medical device companies. Recently, Pravin established a sustainability working group at MTAA to help progress ESG related initiatives for the Australian MedTech sector.   Pravin was also the project lead for MTAA’s major advocacy project for 2023, the Value of MedTech Report, launched at Parliament House in June by the Federal Minister for Health. Pravin has a Master of Public Health from the University of Melbourne (2017), a Bachelor of Medical Science from the University of Sydney (2013) and is currently undertaking a Master of Business Administration at the University of Sydney. Prior to joining MTAA, Pravin worked for 3 years as public policy consultant working on program evaluations for governments and NGO clients across the health, justice and education sectors.

Anthony is a Managing Director at Vista Health and specializes in healthcare consulting in market access, growth strategy & portfolio management spanning 250+ client assignments covering Asia Pacific & Emerging Markets over the past 15 years based within the region.

Previously, he was a Senior Principal for the IQVIA Consulting Group’s Asia Pacific Singapore office where he led client engagements and thought leadership in market entry, innovation & growth strategy, launch planning, operating models & health policy.

Over the course of 25+ years experience in the life science sector beginning at GSK, he has been engaging with and advising multinational & local pharmaceutical, consumer health and med tech corporations, healthcare providers, agencies, health ministries, NGOs & financial firms across Asia Pacific, EMEA & LatAm.

Anthony has expert capabilities in commercial model innovation, launch planning & life cycle management, brand and franchise management, portfolio optimisation, growth strategy, market entry planning, pricing & reimbursement, market access, commercial excellence, health policy, digital health and learning & development.

He holds a BA (Hons) in Modern History, Economics & Politics from London University, PG Diploma in Marketing and is a Chartered Institute of Marketing Member.

Markus Siebert was named Senior Director Health Economics & Reimbursement of the International Division at St. Jude Medical (now Abbott) in January 2012. He is responsible for the development and execution of reimbursement strategies and for guiding the development of health economic evidence in support of Market Access for Abbott’s medical device innovations in Europe, Latin America, Asia and Australia.

Together with his team, he works with multiple stakeholders, including payers and HTA agencies to establish and improve reimbursement for Abbott’s innovations. He is passionate about continuously expanding the impact of the HE&R team by pioneering initiatives on Early Value Assessment, Value Guided Pricing and Market Access for Digital Solutions.

Markus has held several positions at MedTech Europe (previously Eucomed), the European medical technology association, where he served as Chair of the Evidence & Payers Working Group and as Chair of Working Groups on Economics and on Telemonitoring. He was a member of the Cardiovascular Roundtable of the European Society of Cardiology; and a company representative on the HTAi Policy Forum. Markus was co-initiator and Board Member of EHTI, the European Health Technology Institute for Socio-Economic Research and has co-authored several publications in the area of medical device market access.

Markus joined St. Jude Medical in January 2004 after almost seven years at Eucomed (now MedTech Europe), where he headed the Economic Affairs Department.

He holds a Master Degree in Economics from the University of Bochum (Germany) and a Master in Health Economics from VLEKHO, Belgium.

Jeff has more than 25 years’ experience in APAC and emerging markets, working with leading life sciences organisations on issues of strategic and business innovation, and access to healthcare. His experience has encompassed executive positions in the pharmaceutical industry and leadership of Big 4 consulting practices. In market access leadership roles with AbbVie and Novartis, he helped deliver the success of top global brands and he also played a key role in industry policy engagement with PhRMA. He has served on the Board of Governors of AmCham Singapore, lectured on market access strategy at ESSEC Business School, and contributed to the development of the life sciences sector in Singapore through appointments in government and academia. Jeff holds an MA in Asian Studies and Economics from George Washington University. ​

Helsy Pahlemy is a Pharmacist from University of Indonesia. She got a bachelor degree and Magister Program from University of Indonesia. She start career as government employee at Medical Devices Division. She loves to playing tennis dan having guitar lesson on her free time. Rigt Now, she is responsible on sertification on Medical Devices Distributor.

With more than a decade of extensive international experience working in Asian and African countries, Yizhi Lin is a highly regarded expert in the field of Point-of-Care molecular diagnostic Testing. He serves as a council member for the 12th session of the Chinese Anti-Tuberculosis Association and is a founding committee member of the Genetic Testing Subsection of the Chinese Medical Equipment Association. Additionally, he has made significant contributions to medical and telecommunications sectors as an investor and industry expert.Lin and his team have been instrumental in driving innovation in POCT technology, resulting in numerous patent applications and significant contributions to global health initiatives, including the response to COVID-19 and tuberculosis.

Dr Abhishek is a physician, economist, and international affairs graduate with over five years of experience in clinical medicine, community health, academia and multilateral non-governmental organizations. He has worked with patients from socio-economically disadvantaged populations and supported diagnosis, treatment, and continuous care in the domains of maternal and child nutrition, paediatric cancer, chronic paediatric blood disorders, among others. His passion to solve global health challenges and specifically to improve access to healthcare in Low- and Middle-Income Countries has driven him in his academic and experiential pursuits. Currently, he is serving as the Director for The Voices Project, an independent multilateral healthcare research and policy shaping platform in Singapore. The platform convenes experts, patient advocates, pharmaceutical firms, government agencies, academic researchers, and non-governmental organizations to uncover insights into public health challenges and create a well-represented discourse with the aim of driving public health policy reform and improving the lives of people.

Jon Bastow helps organisations accelerate innovation across R&D and Access in healthcare. He helps health systems prepare to harness innovation, by optimising settings of care, and improved linkage across diagnostics, treatments, vaccines and other tools.He brings over 35 years of experience, having led projects across multiple diseases. He has held senior roles in pharmaceutical companies and international organisations such as FIND and The Global Fund, building partnerships between private sector healthcare and tech companies, NGO’s and governments addressing major problems of poverty. Jon is a member of the Chartered Institute of Marketing, holds degrees in Biochemistry and Philosophy and has given lectures at IMD, London Business School, INSEAD and the Graduate Institute in Geneva. He also serves on various boards in the healthcare space and beyond.

Currently, Dr. Ming Xu is a Professor and the Dean of the Department of Global Health at School of Public Health of Peking University, as well as the Associate Dean of the Institute for Global Health and Development of Peking University. He has rich work experience in global health and the development of the healthcare industry. He was the Head of the Department for Emerging Economies and previously the Senior Political Advisor for External Relations at the Global Fund to Fight AIDS, Tuberculosis and Malaria in Switzerland. Prior to that, he was the Vice President of China Chamber of Commerce for the Import and Export of Medicines and Health Products under the Ministry of Commerce of China. Earlier, he served in the United Nations Iraq-Kuwait Observation Mission and the Chinese Embassy in the Republic of Korea. When working with the Global Fund, his focus was mainly on the prevention and control of major infectious diseases and health system strengthening in the implementing countries, and building up collaborations with emerging economies in the health field. When working in China, he participated a lot in formulating the policies and regulations of China’s healthcare industry, ranging from the promotion of trade and investment, regulation of medicinal products, to the enhancement of the international competitiveness of companies. He was the chair and PI of key health projects, and the head or member of evaluation groups to review major health projects at the national level. He currently serves as a member of the Technical Advisory Panel (TAP)of the Pandemic Fund and the World Health Organization’s Technical Advisory Group on Local Production and Technology Transfer of Health Products(TAG-LPTT) .

He got a Ph.D. in industrial economics from Fudan University and completed his post-doctoral fellowship at Guanghua School of Management of Peking University. He has written more than one hundred papers and articles in journals and specialized publications.

Prof. Lan Yao, Dean of School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology, Professor, Doctoral Supervisor, Ministry of Education New Century Excellent Talents, Executive Director of HUST Base of National Institute of Healthcare Security, Director of Primary Health Care Branch of China International Exchange and Promotive Association for Medical and Health Care, Vice Director of Health Insurance Branch of China Health Economics Association, Executive Director of China Health Insurance Research Association, Executive Director of Community Health Association of China, Vice President of Wuhan Medical Insurance Research Association, Vice President of Wuhan Community Health Association, Consulting expert of the Standing Committee of the 15th People’s Congress of Wuhan, Member of the Advisory Committee of Shenzhen Community Health Association. She has served as an advisor to the Health Bureau of the Macao Special Administrative Region. In addition, she was the chief editor of the second edition and third editions of textbook entitled “Medical Security”, with a total of eight books edited. As a project leader, she has presided over more than 80 scientific research projects of the National Natural Science Foundation of China, the National Health Commission, the Ministry of Human Resources and Social Security, the National Development and Reform Commission, the Ministry of Civil Affairs, the Ministry of Science and Technology, the World Health Organization Representative Office in China, the United Nations Children’s Fund, etc. More than 130 academic papers were published in various authoritative journals at home and abroad. She has received 8 awards, including the “China Medical Award” and the Third Prize of Hubei Provincial Scientific and Technological Progress. Main research areas: health economy, health policy, medical security, and primary health care.

Grace Wang is a Partner based in L.E.K.’s Shanghai office. She has over 10 years of experience in strategy consulting, with a focus on the life science and healthcare practice.

Grace has extensive experience supporting international and Chinese clients in medical device, pharmaceutical, life science tools and broader healthcare sectors on a wide range of engagements including growth strategy, pricing and market access, China localization and transaction support​.

Grace graduated from Fudan University with a Double Master’s Degree in International Management from Fudan and Bocconi University​.

Yvonne holds a PhD in Medicine from University of New South Wales and Master of Public Health from Mount Sinai School of Medicine, New York. Her core competencies are real- world clinical evidence generation, health economics, health technology assessments and market access. Yvonne has more than 18 years of working experience across different organizations including academia, government, pharmaceutical and medtech industry. She has established track record publications and worked in the following therapeutic areas: oncology, infectious disease, diabetes, cardiovascular and stroke. She received further training in cancer epidemiology at International Agency for Research on Cancer (IARC), patient centered care at US Patient-Centered Outcome Research Institute (PCORI) and alumni of Eureka 3rd International Certificate Program in Translational Medicine (2010). Yvonne drives multi-stakeholder collaborations to improve patient access to innovative medical technologies across Asia Pacific and she advocates for patient-centered care.

Yawen Wang, M.D., Reviewer, Division of Clinical and Biostatistics I, Center for Medical Device Evaluation (CMDE) of NMPA. She is also a member of Clinical Evaluation Working Group (MDCE) of IMDRF, and participated in the harmonization of Documents of Clinical Evaluation.

Ruslan Tulenov from Kazakhstan, has been living and working in China for 15 years. He is actively engaged in public welfare activities, and has been praised by Chinese President Xi Jinping for donating rare RH-negative blood, also known as “panda blood,” to Chinese patients.

In October 2019, Ruslan Tulenov joined the Hainan International Economic Development Bureau (Hainan IEDB) as the global press officer and deputy director for investment promotion. He has been engaged in promotion of Hainan Free Trade Port, developing relations with foreign investment agencies and broadening global network for Hainan IEDB, trying to help global investors better locate potential projects and partners in the free trade port, and organizing the China International Consumer Products Expo (a.k.a Hainan Expo), the only national-level expo that targets consumer goods.

Studied at Hainan Universtiy and Beijing University of Science and Technology, he holds a bachelor’s degree in Economics.

In 2020, Cindy joined APACMed, offering her dedicated support to the Digital Health Committee. The journey continued in 2021, as she took the helm of the Legal, Ethics, and Compliance Committee. This role enabled her to play a key part in APACMed’s mission to enhance business standards across the APAC region. As 2023 unfolded, she took on the leadership of the APACMed Regulatory Affairs Committee. Through this role, she continues to shape the healthcare landscape in the APAC region, reflecting her unwavering dedication to excellence and innovation.

Before her time at APACMed, Cindy’s career unfolded in France, where she practised as a pharmacist. Her days revolved around ensuring patients received the medications they needed and providing essential guidance. This hands-on experience allowed her to collaborate seamlessly with fellow healthcare professionals, gaining valuable insights into pharmaceuticals, medical devices, and therapeutic approaches that enhance patients’ lives.

Cindy holds a Pharm D from the renowned French University François Rabelais, which laid the foundation for her deep understanding of pharmaceutical sciences. To augment her medical knowledge with business skills, she pursued an Advanced Master’s in Strategy and management of International Business (SMIB) from ESSEC Business School Asia Pacific.

Davina is a dedicated healthcare and technology attorney with significant experience in the public and private sectors. As Senior Regulatory Counsel for International Affairs in the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), Davina plays a pivotal role in shaping international laws and policies which impact the medical device ecosystem. She advises on high profile issues including trade and supply chain, international harmonization, and strategies for ensuring high quality devices. Before joining international affairs, Davina served as Senior Policy Advisor for the Chief of Staff in CDRH and as counsel in the Center for Drug Evaluation and Research (CDER) Office of Compliance. She was inspired to become a government regulator after amassing years of legal and policy experience in a variety of private sector roles. Davina holds a law degree, a master’s degree in Experimental Psychology, and a certificate in business excellence.

Mr Lin Anle is a Senior Regulatory Specialist with the Digital Health Branch. With a focus on evaluating medical device pre-market and post-market submissions, he has also been instrumental in formalising regulatory requirements for MedTech Innovation, including medical devices that incorporate artificial intelligence. He is also involved in device development consultation, which aims to support safe innovation in medical technologies locally. He currently represents Singapore in the International Medical Device Regulatory Forum (IMDRF) working group on Artificial Intelligence/Machine Learning-enabled medical devices.

Dr. Murakami joined PMDA as medical device reviewer in 2005. She’s been involved in international regulatory harmonization activities such as GHTF/IMDRF MC and WGs, ISO TC194 and TC210, Harmonization by Doing (HBD), etc.

After working as medical device QMS auditor in PMDA and as deputy director at Ministry of Health, Labour and Welfare for several years, now she’s in charge of review and consultation for software as a medical device in PMDA.

Tracey Duffy is the First Assistant Secretary of the Medical Devices and Product Quality Division in the Health Products Regulation Group in the Commonwealth Department of Health. The Health Products Regulation Group comprises the Therapeutic Goods Administration and the Office of Drug Control. Her current responsibilities include medical device regulation, Good Manufacturing Practice medicine inspections and Laboratory testing. 

Tracey has held several leadership roles within the Department of Health, including Private Health Insurance, Medical Indemnity Insurance Schemes, and the Office of Health Technology Assessment. Tracey also has private sector experience including consultant advisory roles. 

Hong Liang, Reviewer, Division of Evaluation II, Center for Medical Device Evaluation (CMDE) of NMPA. A committee member of Professional Group of physical therapeutic devices of Chinese Medical Device Classification Technical Committee, and a member of Cybersecurity Working Group of IMDRF, Software Working Group of GHWP , Working Group of WHO&ITU-AI4H. Familiar with the technical fields in software, cybersecurity, artificial intelligence, and digital therapeutics of medical devices.

Dr. Muralitharan Paramasua, is the Chief Executive of Medical Device Authority, Ministry of Health Malaysia since 15th February 2023. Before being appointed as Chief Executive in February 2023, Dr. Muralitharan served in Ministry of Health Malaysia as an Administrative and Diplomatic Officer in various positions for 9 years.

Prior to joining MOH, Dr. Muralitharan was also once served at the Ministry of Natural Resources and Environment for 7 years from 2011
to 2017 and was responsible for international affairs of the ministry including free trade negotiations with different countries.

Dr. Muralitharan earned his PhD in International Economy from University of Malaya. He received his Master’s Degree in Criminal Justice, and his Bachelor’s Degree in Biohealth Science from the University of Malaya.

Bach Minh Hung is an Officer with the Infrastructure and Medical Device Administration (IMDA) under the Ministry of Health, Vietnam. He participates in developing legal documents on medical equipment management in Vietnam and appraising applications for import licenses and registration for circulation of medical devices in Vietnam. He also provides guidance on training and preparation of registration documents in Vietnam, contributing significantly to the development of crucial regulatory documents.

Vo Duong Phan Nghia, is an Officer with the Infrastructure and Medical Device Administration (IMDA) under the Ministry of Health, Vietnam who actively contributes to the development of essential legal documents for the effective management of medical equipment in Vietnam. He participates in developing legal documents on medical equipment management in Vietnam and appraising applications for import licenses and registration for circulation of medical devices. He also provides guidance on training and preparation of registration documents in Vietnam.

Seasoned Global Healthcare Leader, Anh Bourcet (Nguyen) has a 15-year track record of driving excellence and transformation in Market Access for pharmaceuticals, medical devices and diagnostics. Known for establishing strategic multi-stakeholder partnerships, Anh has shaped access policies, built the Market Access function from the ground up, transforming clinical practices, for optimised patient access to innovations. Her various roles in Medical Affairs, Health Economics & Market Access and Regulatory Policy, across diagnostics, medical devices and pharmaceutical industries, enable her to have a broad perspective on different levers of market access. In particular, she has played a key role in shaping market access policies for Public Health and Digital Health in Asia-Pacific for a more sustainable care.

Anh held leadership positions in Abbott and Johnson & Johnson in APAC, and at the French Health Safety Agency (ANSM). She is currently Strategic Advisor for APACMed (Asia-Pacific Medical Technology Association).

Her contributions to the field have been widely recognized, and she has been a regular speaker at major international conferences, providing valuable insights on topics such as digital health, health data, access and reimbursement.

Nordin Charafi is a Healthcare Market Access Executive with a broad experience in related strategy development and implementation in the Life Sciences industry. Nordin has a deep understanding of major worldwide healthcare payment systems, honed through years of hands-on, practical experience and study, which he has leveraged to inform a variety of reimbursement strategies and actions for diverse healthcare technologies.

Nordin is currently the Market Access lead for the Asia Middle East and Africa region at Illumina and prior to that he was responsible for the Market Access activities for the West European region. As part of his role, Nordin is playing a proactive role in engaging with payers to understand their requirements for the assessment and reimbursement of Illumina’s genomic tests.

Nordin is a French national who holds a Masters degree in Business from ESSEC Business School and a Masters degree in Genetics from the University of Paris.

Dr. Michael Wilson is Professor of Pathology at the University of Colorado School of Medicine and Director of the Department of Pathology and Laboratory Services at Denver Health, the safety net health system in Denver. He has been an academic pathologist for over 30 years.

Dr. Wilson graduated from medical school and trained in anatomic and clinical pathology at the University of Colorado School of Medicine. He trained in Medical Microbiology at Duke University.

Since 2008, Dr. Wilson’s academic focus has been on the problem of access to diagnostic services in low-income and middle-income countries. He was a lead author on the Lancet Series on Pathology and Laboratory Medicine in Low-Income and Middle-Income Countries and is currently Deputy Co-Chair of the Lancet Commission on Diagnosis. He has served as a WHO adviser on the Expert Group for Priority Medical Devices for Cancer Management and currently serves on the WHO SAGE-EDL.

Dr. Bill Rodriguez joined FIND as Chief Executive Officer on 1 July 2021, following an earlier tenure as Chief Medical Officer between 2015 and 2017. He was previously Managing Director at the Draper Richards Kaplan Foundation, a global venture philanthropy firm supporting early-stage, high-impact social enterprises. A physician and entrepreneur, he has extensive experience across both private and public sectors, founding his own diagnostics company, Daktari Diagnostics. As a faculty member at Harvard Medical School, he established a research programme on diagnostics and operational research in global health. He left Harvard in 2003 to become the Chief Medical Officer of the William J. Clinton Foundation, where he helped broker pricing agreements of HIV drugs and diagnostic tests between African and Asian governments and the major suppliers. Bill is a highly respected figure in the global health community, serving as advisor to the World Health Organization, Bill & Melinda Gates Foundation, national governments on global HIV, tuberculosis, Ebola and COVID-19, as well as numerous established and start-up for-profit and not-for-profit social enterprises focused on global health. Bill is a graduate of Brown University and the Yale University School of Medicine, and trained in infectious disease medicine at the Brigham & Women’s Hospital in Boston, where he served as chief medical resident.

Management and Leadership professional with experience across industries, in managing complex Research and Development R&D, Technology Transfer, and operations in highly regulated environments. Experience in leading cross-functional teams to achieve goals and milestones with effective communication at all levels. Keen in establishing relationships with third parties from the business world.

Joanne Yoong, PhD, is an applied micro-economist and interdisciplinary researcher whose work addresses decision-making for health, financial and social well-being, and the design and evaluation of interventions, technologies and systems that support vulnerable populations. Dr. Yoong holds multiple faculty appointments and is the author of over one hundred peer-reviewed articles in leading economics, medical and public health journals. She has worked on projects around the world including Singapore, Malaysia, the United States, India, China, Ghana, Kenya, Cambodia, Indonesia and Iraqi Kurdistan. Dr. Yoong received her PhD in Economics at Stanford University as an FSI Starr Foundation Fellow after an early career in financial services, and her AB summa cum laude in Economics and Applied and Computational Mathematics from Princeton University.

Arika Garg is an Associate Director with the Global Diagnostics team at the Clinton Health Access Initiative (CHAI). She has worked in public health for close to a decade – first, in a research capacity on U.S. domestic health policy, and for the past five years in global health with CHAI. In her current role, Arika oversees and manages CHAI’s diagnostics portfolio across eight countries in the Asia-Pacific region, and is the lead for CHAI’s regional external engagement within the diagnostics space.

Arika holds an MBA from the Yale School of Management and was a management consultant with Bain & Company prior to joining CHAI.

Dr. Karthik G M holds over 15 years of combined expertise in Regulatory Affairs (Medical Devices) and Biomedical Research & Development. As Associate Director of Regulatory Affairs for Asia, Middle East, and Africa at Guardant Health, he steers regulatory strategies and product submissions across these markets. Notably, at Singapore’s Health Sciences Authority (HSA), he was involved in drafting Product Specific Regulatory guidelines (NGS) for Singapore. His Ph.D. in Biomedical sciences from Karolinska Institutet, Sweden is accompanied by 8 impactful research articles. By fusing regulatory prowess with scientific insight, Dr Karthik G M propels innovation while ensuring compliance, underscoring his leadership, and lasting impact in both biomedical and regulatory domains.

Prof Tony Lim is Senior Consultant and Chairman, Division of Pathology in Singapore General Hospital and Academic Chair of the SingHealth Duke-NUS Pathology Academic Clinical Programme. He is actively involved in research focusing on molecular genetics, personalised medicine and the study of lung, liver and gastrointestinal diseases, directing many research initiatives which are instrumental in translating discovery into diagnostics. As the Head of Section of Translational Pathology Centre (TPC) and the Clinical Director in Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Prof Lim collaborates with many industry and non-industry partners, contributing his clinical expertise to numerous research projects leading to new developments and findings published in many peer-reviewed journals. In addition to research, he has a passion in teaching, and is a Clinical Professor in Duke-NUS Medical School. Prof Lim is also a Clinical Physician Faculty in the SingHealth Pathology Residency Programme.

Mr Yong’s healthcare career spans two decades as a business and operational leader with IHH Healthcare (IHH), Raffles Medical Group (RMG), and Alexandra Hospital (AH). 

He is the Chief Operating Officer (COO) of IHH Singapore and concurrently the Chief Executive Officer (CEO) of Asia Pacific’s renowned private quaternary institution at Mount Elizabeth Hospital (MEH). 

As Country COO, he drives the ecosystem and operational strategies of IHH’s Singapore assets comprising the acute hospitals (Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East Hospitals), and the primary, ambulatory and diagnostics units (Parkway Shenton, Parkway MediCentre, Parkway Radiology and Parkway Laboratories).  
As MEH CEO, he is the Principal Officer and is responsible for driving the strategic direction, operational excellence, and financial performance of the 345-bed multi-specialty institution with a community of 650 doctors and 1,300 staff. He also leads the S$350M multi-year live site hospital redevelopment project – Renaissance. 

Shan is the head of WHO Collaborating Centre for Digital Health, the vice-chair of ITU&WHO Artificial Intelligence for Health focus group(FG-AI4H). She works for the China Academy of Information and Communications Technology (CAICT) as deputy director of the International Collaboration Centre and the Chief Officer on International Affairs of the Health big data and network innovation centre. She was elected in the roster of WHO digital health expert, and acts as the co-chair of the Ad-hoc group of the digital technologies on COVID health emergency (AHG-DT4ER), member of the WHO Smart Vaccination Certificate (SVC) working group and cybersecurity working group in the International Medical Device Regulators Forum (IMDRF).

Mr Setiaji is an Expert Advisor of Health Technology to The Minister of Health in Indonesia. Setiaji, a digital leader and a civil servant with more than 10 years of experience in digital transformation and smart city development and digital transformation in the line ministries and government agencies in Indonesia. His experience leading the West Java Digital Services, Jakarta Smart City grows my expertise in information technology as he was a graduate of information technology engineering. All his expertises and experiences are being applied to serve the public effectively, efficiently, and impactful to the citizens based on data and technology utilization. He is a team builder who is very attentive to the needs of stakeholders and leaders. He is a digital leader with a warm & friendly attitude always! He plays an essential role in providing practical solutions that directly impact and improve public services. He has won various National and International awards in Digital Transformation: Top CIO on Digital Implementation, IT Works 2021 and The World CIO 200 Awards–SEA Edition, Global CIO Forum 2021.

Dr. Sidharth is the Medical Director & Head, Medical Portfolio Management for Prudential Singapore. He is responsible for providing solutions to achieve profitable and sustainable metrics for Prudential’s Health Insurance business and driving a cross functional strategy, which includes development and implementation of initiatives related to long-term healthcare insurance models, both on a digital and conventional platform.

Dr. Sidharth has an extensive Health Insurance & Reinsurance background spanning over 20 years. Prior to joining Prudential, he was responsible for providing expertise and delivering solutions related to health insurance product development and operations, including health
underwriting, claims and health-tech solutions, to Insurers in South & Southeast Asia. He also has significant operational expertise in managing health KPO’s and TPA’s in India.

Dr. Sidharth is a regular speaker at Global Health Insurance forums and drives industry thought leadership related to health insurance matters. Currently, he is serving as the Deputy Convenor of the Health Insurance Sub-committee, LIA Singapore. He is a Physician by training and was actively involved in clinical practice prior to joining the Health Insurance
industry.

Wai Chiong led, started and grew several projects within the InHealth programme to address both social and environmental determinants of health. Currently as Senior Consultant of MOHT, he continues to lead Financing Redesign, the mindline digital mental wellbeing platform, and various horizontal enabling initiatives across MOHT. Prior to joining MOHT, Wai Chiong was Partner and Healthcare Sector leader for Deloitte Southeast Asia. As a management consultant in private sector, he advised governments, investors, life sciences companies, providers and payers globally. His projects included business strategy advisory to biomedical and health-tech start-ups, new product development, regulatory and market entry, commercial feasibility of healthcare investments, mergers & acquisitions, amongst others.

Dr. Rajendra Pratap Gupta is behind many path- breaking initiatives and organizations, working for Digital Health. He is also the former advisor to the Health Minister of India. He is the chair of the Commonwealth AI Consortium for Capacity Building, a Member & contributor of various WHO initiatives; Board Member of the International Society for Telemedicine & eHealth (ISfTeH); Member of the Steering Committee, Global Digital Health Index; Chairman of the Capacity Building Working group at the International Society for Telemedicine & eHealth (ISfTeH, Switzerland); Member of the World Economic Forum Expert Network; Chairman of the Dynamic Coalition on ‘Internet & Jobs’ at IGF, United Nations & Chairman of the Dynamic Coalition on Digital Health at IGF, United Nations. He has co-authored the Global eHealth Diffusion report (WHO). He is the founder of Health Parliament and Digital Health Academy & author of the best-seller ‘Digital Health – Truly Transformational’.

Louise Agersnap (MA and B.A. Pol. Sci.; B.H.A.) is an innovation and change leader with extensive experience & knowledge of global health, development, and the innovation ecosystem, acquired through 20+ years in the United Nations, private sector & government, NGO, and academia. 
Creativity and entrepreneurship are at the heart of her work, demonstrated by the track record of innovations and novel ‘start-up’ initiatives throughout her career, leading change from within and expanding organizational and cultural boundaries of government and global, multilateral organizations to achieve greater outcomes. Throughout, she draws on her own artist background, political science academic training, and passion for positive transformation and impact.

Currently leading the Innovation Hub at the World Health Organization, at times acting Director for the Department for Digital Health and Innovation, Louise Agersnap leads the strategy shaping and execution of WHO’s innovation in health mission and promotes the Global Strategy for Digital Health. Her focus two-fold: scaling the impact of evidence-based interventions through innovation to address neglected problems and people in low- resource settings and enhancing organizational culture and capacities for creative problem solving.

All along her professional career, Louise Agersnap is a selling artist, amongst other places featured at the International Contemporary Art Fair in Luxembourg, at the Van Gogh Art Gallery in Madrid, Spain.

Carla leads global digital, R&D, and regulatory policy for Johnson & Johnson’s Government Affairs & Policy (GA&P) policy team across the pharmaceutical and medical device sectors. She drives work on a variety of policy issues including AI and data ethics, health equity, and regulatory modernization and represents GA&P in several internal and external fora including the Johnson & Johnson Data Science and Data Management Councils. Prior to joining Johnson & Johnson, Carla was an attorney and team leader in FDA’s Office of the Chief Counsel where she advised the Center for Drug Evaluation and Research on legal and policy issues. Living in Kensington MD with her spouse and sixteen year old son, Carla enjoys traveling, baking, trying to keep her many plants alive, and book clubs. She serves on the board of the Educational Foundation for her son’s school. Carla is a graduate of Washington University in St. Louis and has a JD from Yale Law School and an LLM from Georgetown University Law Center. 

Birgitta Riani joined as Assistant Manager – Digital Health, APACMed in Aug 2023 and has previously supported the Digital Health Committee from Jul – Dec 2022. She’s deeply committed to facilitating collaboration within the Digital Health Committee and enhancing the accessibility of new digital health solutions across the Asia Pacific region.

Prior to joining APACMed, Ria worked at a foreign policy think-tank in Jakarta, Indonesia. Her role involved managing cross-country projects and engaging stakeholder across ASEAN, Japan, and South Korea.

Ria holds a Bachelor’s degree in Social Science in International Relations and Peace Studies from Ritsumeikan Asia Pacific University in Japan, and a Master’s degree in Management from ESSEC Business School in France. She is also a proficient multilingual in English, Bahasa Indonesia, Korean and Japanese.

Chris Ahern has advised on Australian corporate law for over 20 years. His practice focuses on M&A, particularly in the technology and energy sectors. He has advised on numerous transactions for Fortune 500 companies, and his experience in corporate law covers the full range of M&A, including court-approved mergers by scheme of arrangement, venture capital, development capital, private placements, public to private transactions, as well as private company M&A work. Chris acted for First Data Corporation on its $22 billion acquisition by KKR, Lowe’s Home Improvement on their multibillion dollar joint venture with Australia’s largest retailer, USG on their $2.5 billion pan-Asian joint venture with Boral, and multiple acquisitions in the technology and energy sectors. Chris also has significant experience in distressed M&A, having acted for Lucent on the $2.5 billion collapse of One-Tel (including the appointment of a Receiver over most of the assets of One-Tel and the workout that followed), Lehman Brothers Holdings on their collapse (including advising on the DOCA between the company and CDO holders), and acting for Cyrus Capital on their bid for Virgin Australia, Australia’s second airline. He also advises on joint ventures (incorporated and unincorporated) and complex alliance arrangements in the technology and fintech sectors and is skilled at dealing with intellectual property and software licensing issues that arise in such transactions, including open source software obligations, payment processing, and joint development arrangements. Chris commenced the Australian law practice for Jones Day in 2006 and has been named in Chambers legal directories as a leading lawyer since 2001. Prior to joining Jones Day, he was a partner at one of Australia’s national law firms.

Sushma Jobanputra, the Partner-in-Charge of the Singapore Office, has been advising clients for more than three decades on banking, restructuring, and corporate matters. She has practiced in London, Toronto, Paris, and Singapore, and her practice includes structured, acquisition, and trade finance as well as cross-border debt restructuring across Asia including Singapore, India, Indonesia, Japan, Malaysia, Vietnam, and the Philippines. Sushma’s financial institution clients include Standard Chartered Bank, DBS Bank, JBIC, Asian Development Bank, BNP Paribas, and Société Générale. She also has represented a significant number of corporate clients, including IBM, Procter & Gamble, Hyatt Corporation, Godrej Group, Micron Technologies, Temasek, Crescent Point, L Catterton, Tikehau, Boeing Corporation, Chevron Corporation, Trafigura, and the Tata Group. Before joining Jones Day, Sushma was a managing director at Barclays Capital, heading a team in the structured transactions department, with responsibility on behalf of the bank for the execution of all large complex structured transactions with other financial institutions and multinationals. Prior to that she was a partner at a Magic Circle firm in London where her practice focused on structured and acquisition finance. Sushma serves on the following committees: National University of Singapore’s Law Advisory Council, which supports and advances the Law Faculty in its education, research, and service mission; Expert Panel for the Singapore Management University Centre for Commercial Law in Asia; Organising Committee for the Singapore Academy of Law Annual Lecture; Legal Services Committee of the Singapore International Chamber of Commerce; Documentation Committee for the Asian Pacific Loan Market Association Singapore; and Advisory Committee to the Board of WIMAR (Women in Mining and Resources, Singapore).

Dean Ho is a Provost’s Chair Professor in the Departments of Biomedical Engineering and Pharmacology, Director of the N.1 Institute for Health, and Head of the Department of Biomedical Engineering at the National University of Singapore. Ho is an internationally recognised leader in digital medicine. His team has pioneered the use of artificial intelligence towards life-saving outcomes in cancer, infectious diseases and beyond. Most recently, Ho led a team to address new areas of innovation, ranging from the design of novel treatments against Covid-19 to addressing food security. Ho was also recently elected a Fellow of the American Association for the Advancement of Science – the only Singapore-based honouree in the 2021 Class. The lifetime honour is one of the most prestigious among innovators worldwide. His discoveries have been featured on CNN and CNA, and in The Economist, National Geographic, Forbes and other outlets. Ho is also a subgroup lead in the World Health Organization Working Group on regulating AI for healthcare applications.

Chong Seow Wei is the regional senior editor of Tatler Gen.T, Tatler Asia’s community-focused content and events platform for the Leaders of Tomorrow. Together with her team of editors, who are located across seven markets, she is pushing the brand’s mission to discover, support and catalyse the impact of Asia’s most promising young leaders.